Hereditary spherocytosis
Template:DiseaseDisorder infobox
|
Hereditary spherocytosis Microchapters |
|
Differentiating Hereditary spherocytosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hereditary spherocytosis On the Web |
|
American Roentgen Ray Society Images of Hereditary spherocytosis |
|
Risk calculators and risk factors for Hereditary spherocytosis |
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Zahir Ali Shaikh, MD[2]
Overview
Hereditary spherocytosis is a genetically-transmitted form of spherocytosis, an auto-hemolytic anemia characterized by the production of red blood cells that are sphere-shaped rather than donut-shaped, and therefore more prone to hemolysis.
Historical Perspective
- Hereditary spherocytosis was first described in 1871.[1]
- It is the commonest cause of inherited chronic hemolysis in the northern europe and north america.[2]
Classification
- Hereditary Spherocytosis classified on basis of underlying defect in protein and also on the basis of severity of hemolysis.
- Classification of hereditary spherocytosis on the basis of clinical severity.[3]"GeneReviews® - NCBI Bookshelf".
| Locus | Gene | Protein | Inheritance | Severity | Comment |
|---|---|---|---|---|---|
| SPH1 | ANK1 | Ankyrin-1 | AD/AR | mild-moderate/moderately severe-severe | often transfusion dependant |
| SPH2 | SPTB | Spectrin beta chain,erythrocytic | AD/AR | mild-moderate/severe | 1 fatal infantile case described |
| SPH3 | SPTA1 | Spectrin alpha chain,erythrocytic1 | AR | severe | transfusion dependant |
| SPH4 | SLC4A1 | Band3(anion transport protein) | AD | mild-moderate | certain SLC4A1 variants cause disease only when biallelic |
| SPH5 | EPB42 | Protein 4.2 | AR | mild-moderate | 1 moderately severe case described |
| Classification | Mild | Moderate | Severe |
|---|---|---|---|
| Hemoglobin (g/dl) | 110-150 | 80-120 | 60-80 |
| Reticulocyte count (%) | 3-6 | >6 | >10 |
| Bilirubin (ug/l) | 17-34 | >34 | >51 |
| Splenectomy | usually not required | indicated during school age, usually before puberty | necessary - delay until 6 years of age if possible |
Pathophysiology
- The defects in hereditary spherocytosis lie in the cell membrane.[3]
- The proteins essential for integrity of membrane structure lie immediately under the lipid bilayer, horizental aplha & beta spectrin molecules form heterodimers with linkage to vertical elements- ankyrin, proteins 4.1 & 4.2 and band 3 (a transmembrane protein).
- Different genes code for each of these proteins, therefore hereditary spherocytosis is a hetrogenous disorder which can result from a defect in any one of these proteins.
- The destabilization of membrane leads to both abnormal morphology and reduced red cell life span.
- The shorter the life span of red blood cells, the worse the clinical effects.
- Genetic defect and clinical severity tend to be fairly constant within a given family,but between family varies from mild asymptomatic hemolysis to severe continuous anemia with jaundice.
Causes
- Hereditary spherocytosis is caused by a variety of genetic mutations.[4][5]
- There are 05 genes associated with hereditary spherocytosis including, alpha spectrin (SPTA1), beta spectrin (SPTB), ankyrin (ANK1), band3 (SLC4A1) and protein 4.2 (EPB42).
- Mutations in one or more of hereditary spherocytosis related genes can cause membrane protein deficiency leading to hereditary spherocytosis.
| Gene | Chromosome Location | Membrane Protein | Prevalent Mutations | Heredity | Associated Disease |
|---|---|---|---|---|---|
| ANK1 | 8p11.2 | Ankyrin-1 | frameshift, nonsense, splicing, novel mutations | autosomal dominant, autosomal recessive | hereditary spherocytosis |
| SLC4A1 | 17q21 | Band3 | missense,frameshift,polymorphism | autosomal dominant | hereditary spherocytosis,distal renal tubular acisosis |
| SPTA1 | 1q22-q23 | alpha spectrin | SpaLEPRA allele, splicing, frameshift | autosomal recessive | hereditary spherocytosis, hereditary eliptocytosis, hereditary pyropoikilocytosis |
| SPTB | 14q23-q24.1 | beta spectrin | splicing, frameshift, nonsense, novel mutations | autosomal dominant | hereditary spherocytosis, hereditary eliptocytosis, hereditary pyropoikilocytosis |
| EBP42 | 15q15-q21 | protein 4.2 | missense, nonsense | autosomal recessive | hereditary spherocytosis |
Differentiating Hereditary Spherocytosis from Other Diseases
- Hereditary spherocytosis presents with hemolysis, therefore should be differentiated from following diseases.[6][5]
- Autoimmune hemolysis
- Thermal injury
- Clostridial septicemia
- Wilson disease
- Hemoglobinopathies
- Hereditary stomatocytosis
- Congenital dyserythrpoietic anemia type II
Epidemiology and Demographics
- Hereditary spherocytosis is reported worldwide in all racial and ethnic groups.[7]
- It is the most common inherited anemia in the northern European ancestry and north america.[8]
- The reported incidence of hereditary spherocytosis is 1 in 5000 births.[9]
Risk Factors
- The risk factors for this condition have not yet been properly identified.
- However, having a family member with this condition can increase your susceptibility to this disease. The condition is also most common in individuals of North European origin although it has been found to arise in people of all races.
Screening
- It is also important to test newborns of affected parents for HS, as affected newborns may have severe hyperbilirubinemia and anemia. This may be done by a clinician with expertise in hemolytic anemias or by a genetic counselor. It is possible for an individual with no hemolysis, no spherocytes on the blood smear, and a normal reticulocyte count to be a carrier of HS, which may be relevant in certain families.
Natural History, Complications, and Prognosis
Natural History
- Disease severity and age of presentation — HS can present at any age and with any severity, with case reports describing a range of presentations, from hydrops fetalis in utero through diagnosis in the ninth decade of life.
- The majority of affected individuals have mild or moderate hemolysis or hemolytic anemia and a known family history, making diagnosis and treatment relatively straightforward. Individuals with significant severe hemolysis may develop additional complications such as jaundice/hyperbilirubinemia, folate deficiency, or splenomegaly.
Complications
Common complications of hemolysis include neonatal jaundice, splenomegaly, and pigment gallstones.
- Neonatal jaundice — HS may present in the neonatal period with jaundice and hyperbilirubinemia, and the serum bilirubin level may not peak until several days after birth. Some experts have proposed that HS is underdiagnosed as a cause of neonatal jaundice. A requirement for phototherapy and/or exchange transfusion during this period is common.
- Splenomegaly — Splenomegaly is rare in neonates, but can often be seen in older children and adults with HS. Early reports of family studies found palpable spleens in over three-fourths of affected members, but this may reflect a skewed population with the most severe disease. In these studies, the relationship between disease severity and splenic size was not linear.
- Pigment gallstones — Pigment (bilirubin) gallstones are common in individuals with HS and may be the presenting finding in adults. Gallstones are unlikely before the age of 10 years but are seen in as many as half of adults, especially those with more severe hemolysis. Gallstones appear to be more common in individuals with Gilbert syndrome.
Prognosis
- Overall, the long-term outlook for people with hereditary spherocytosis (HS) is usually good with treatment. However, it may depend on the severity of the condition in each person.
- People with very mild HS may not have any signs or symptoms unless an environmental "trigger" causes symptom onset. In many cases, no specific therapy is needed other than monitoring for and watching for signs and symptoms.[8] Moderately and severely affected people are likely to benefit from splenectomy.
- Most people who undergo splenectomy are able to maintain a normal hemoglobin level.[4] However, people with severe HS may remain anemic post-splenectomy, and may need blood transfusions during an infection.
Diagnosis
Diagnostic Criteria
- Newly diagnosed patients with a family history of HS, typical clinical features and laboratory investigations (spherocytes, raised mean corpuscular haemoglobin concentration [MCHC], increase in reticulocytes) do not require any additional tests (grade 1 recommendation, grade A evidence).
- If the diagnosis is equivocal, a screening test with high predictive value for HS is helpful. The recommended screening tests are the cryohaemolysis test and EMA binding (grade 1 recommendation, grade A evidence). (Confirmation).
- Gel electrophoresis analysis of erythrocyte membranes is the method of choice for diagnosis of atypical cases.
History and Symptoms
- As in any other chronic hemolytic states, the signs and symptoms of hereditary spherocytosis (HS) include mild pallor, intermittent jaundice, and splenomegaly. However, signs and symptoms are highly variable. Anemia or hyperbilirubinemia may be of such magnitude as to require exchange transfusion in the neonatal period. The disorder also may escape clinical recognition altogether. Anemia usually is mild to moderate, but is sometimes very severe and sometimes not present.
- Symptoms of hereditary spherocytosis include:
- Yellowing of the skin and eyes (jaundice)
- Pale coloring (pallor)
- Fatigue
- Irritability
- Shortness of breath
- Weakness
Physical Examination
- Splenomegaly is the rule in HS. Palpable spleens have been detected in more than 75% of affected subjects. The liver is normal in size and function.
- Other important clues are jaundice and upper right abdominal pain indicative of gallbladder disease. This is especially important if the patient has a family history of gallbladder disease.
- Any patient who presents with profound and sudden anemia and reticulocytopenia with the aforementioned physical findings also should have HS in the differential diagnosis.
Laboratory Findings
Initial testing
- CBC and RBC indices – All individuals with suspected HS based on family history, neonatal jaundice, or other findings should have a complete blood count (CBC) with reticulocyte count and red blood cell (RBC) indices. The mean corpuscular hemoglobin concentration (MCHC) is often the most useful parameter for assessing spherocytosis; an MCHC ≥36 g/dL is consistent with spherocytes. A low mean corpuscular volume (MCV) is also helpful in some cases, especially in neonates, but variable degrees of reticulocytosis make the MCVless useful in older children and adults.
- Blood smear review – All individuals with suspected HS should have a blood smear reviewed by an experienced individual. In a peripheral blood smear, the abnormally small red blood cells lacking the central pallor i.e. spherocytes are seen. Other abnormal RBC shapes, and the degree of polychromatophilia, which reflects reticulocytosis.
- Coombs testing – If hemolysis is present, Coombs testing (also called direct antiglobulin testing [DAT]) is usually done to eliminate the possibility of immune-mediated hemolysis, which may be due to hemolytic disease of the fetus and newborn (HDFN) in neonates or autoimmune hemolytic anemia (AIHA) in older children and adults. The results of testing may also be useful to the transfusion service if transfusion is indicated. Coombs testing in HS is negative.
Confirmatory tests
- EMA binding ●Osmotic fragility ●Glycerol lysis ●Cryohemolysis
Imaging Findings:
- There are no particular other imaging findings associated with HS.
Other Diagnostic Studies:
- In certain atypical cases in which further characterization of the RBC cytoskeletal/membrane proteins is needed, gel electrophoresis can be done using RBC ghosts, or DNA sequencing can be performed.
Treatment
Medical Therapy
- As with most inherited hemolytic anemias, treatment is directed at preventing or minimizing complications of chronic hemolysis and anemia. There are no specific treatments directed at the underlying red blood cell (RBC) membrane defect.
- If a neonate is suspected of having HS (eg, based on positive family history and neonatal jaundice), treatment can be initiated for HS without awaiting diagnostic confirmation. This may include therapy for hyperbilirubinemia and, in severe cases, transfusion or even exchange transfusion [83
- The goals of pharmacotherapy for hereditary spherocytosis are to reduce morbidity and prevent complications. Folic acid supplementation is indicated to prevent megaloblastic crisis.
Surgery
- Generally, the treatment of HS involves presplenectomy care, splenectomy, and management of postsplenectomy complications.
- In pediatric cases, splenectomy ideally should not be performed until a child is older than 6 years because of the increased incidence of postsplenectomy infections with encapsulated organisms such as S pneumoniae and H influenzae in young children.
- Partial splenectomies are increasingly used in pediatric patients, as this approach appears to both control hemolysis and preserve splenic function.
Prevention
In general, once the diagnosis and baseline severity of HS in a child are established, it is not necessary to perform repeated blood tests unless there is an additional clinical indication (such as intercurrent infection and pallor, or an increase in jaundice). A routine annual review is usually sufficient together with an open door policy for potential complications such as parvovirus infection, or abdominal pain, which may trigger investigation for gallstones.
Case Studies
Related Chapters
External links
References
- ↑ Sayeeda Huq, Mark A. C. Pietroni, Hafizur Rahman & Mohammad Tariqul Alam (2010). "Hereditary spherocytosis". Journal of health, population, and nutrition. 28 (1): 107–109. PMID 20214092. Unknown parameter
|month=ignored (help) - ↑ Sayeeda Huq, Mark A. C. Pietroni, Hafizur Rahman & Mohammad Tariqul Alam (2010). "Hereditary spherocytosis". Journal of health, population, and nutrition. 28 (1): 107–109. PMID 20214092. Unknown parameter
|month=ignored (help) - ↑ 3.0 3.1 Bolton-Maggs, P H B (2004). "Hereditary spherocytosis; new guidelines". Archives of Disease in Childhood. 89 (9): 809–812. doi:10.1136/adc.2003.034587. ISSN 0003-9888.
- ↑ He, Ben-Jin; Liao, Lin; Deng, Zeng-Fu; Tao, Yi-Feng; Xu, Yu-Chan; Lin, Fa-Quan (2018). "Molecular Genetic Mechanisms of Hereditary Spherocytosis: Current Perspectives". Acta Haematologica. 139 (1): 60–66. doi:10.1159/000486229. ISSN 0001-5792.
- ↑ 5.0 5.1 Perrotta, Silverio; Gallagher, Patrick G; Mohandas, Narla (2008). "Hereditary spherocytosis". The Lancet. 372 (9647): 1411–1426. doi:10.1016/S0140-6736(08)61588-3. ISSN 0140-6736.
- ↑ Robert D. Christensen, Hassan M. Yaish & Patrick G. Gallagher (2015). "A pediatrician's practical guide to diagnosing and treating hereditary spherocytosis in neonates". Pediatrics. 135 (6): 1107–1114. doi:10.1542/peds.2014-3516. PMID 26009624. Unknown parameter
|month=ignored (help) - ↑ Silverio Perrotta, Patrick G. Gallagher & Narla Mohandas (2008). "Hereditary spherocytosis". Lancet (London, England). 372 (9647): 1411–1426. doi:10.1016/S0140-6736(08)61588-3. PMID 18940465. Unknown parameter
|month=ignored (help) - ↑ Sayeeda Huq, Mark A. C. Pietroni, Hafizur Rahman & Mohammad Tariqul Alam (2010). "Hereditary spherocytosis". Journal of health, population, and nutrition. 28 (1): 107–109. PMID 20214092. Unknown parameter
|month=ignored (help) - ↑ Sayeeda Huq, Mark A. C. Pietroni, Hafizur Rahman & Mohammad Tariqul Alam (2010). "Hereditary spherocytosis". Journal of health, population, and nutrition. 28 (1): 107–109. PMID 20214092. Unknown parameter
|month=ignored (help)